Levonorgestrel - Schering Oy

Drug Profile

Levonorgestrel - Schering Oy

Alternative Names: BAY86-5028; Levonova; Menopausal levonorgestrel system; Mirena; MLS

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schering Oy
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menorrhagia; Pregnancy; Uterine diseases
  • Phase III Menstruation disorders
  • No development reported Menopausal syndrome

Most Recent Events

  • 05 Dec 2016 Bayer plans the phase III Mirena Extension Trial for Contraception in USA (Intrauterine) (NCT02985541)
  • 01 Dec 2016 Phase-III clinical trials in Menstruation disorders in USA (Intrauterine) (NCT02985541)
  • 01 Dec 2016 Bayer initiates enrolment in the phase III Mirena Extension Trial for Contraception in USA (Intrauterine) (NCT02985541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top